Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 9;11(7):126. doi: 10.1038/s41408-021-00518-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — In the frontline setting, patients are treated according to age. In patients aged <60 years, the treatment options can be either immunotherapy (BV) combined with AVD or risk-adapted PET-guided approaches using ABVD and/or eBEACOPP. In patients aged >60 years, the intensity of therapies should be adapted to comorbidities. In the relapsed setting, chemoimmunotherapeutic or chemotherapy-free approaches can be used. ASCT is recommended for fit patients followed by BV maintenance for high-risk patients (a shorter duration of BV or the use of anti-PD1 mAbs alone or in combination with BV may be considered). Beyond third-line therapy, immunotherapy can be used as single agent or in combination. Also, patients can be included in clinical trials using novel agents or cellular therapy. Allo-SCT remains the standard of care for fit and responding patients. PT-Cy should be considered as GvDH prophylaxis for all patients undergoing allo-SCT, even in the non-haploidentical settings. HL: Hodgkin Lymphoma; ABVD: Adriamycin, Bleomycin, Vincristine, Dacarbazine; eBEACOPP: bleomycin, etoposide, doxorubicin (aka adriamycin),cyclophosphamide, vincristine (aka oncovin), procarbazine, prednisolone; PET: positron emission tomography; BV: brentuximab vedotin; AVD: Adriamycin, Vincristine, Dacarbazine; GVD: gemcitabine, vinorelbine, liposomal doxorubicin; CR: complete response; ICE: ifosfamide, mesna, carboplatin, etoposide; ASCT: autologous stem cell transplantation; PD1: programmed cell death 1; mAbs: monoclonal antibodies; CPI: checkpoint inhibitors; Allo-SCT: allogeneic stem cell transplantation; PT-Cy: post-transplant cyclophosphamide; GvHD: graft-versus-host disease.